IP Library Granted Patent US 9,109,199
Granted Patent B2
US 9,109,199 · App. 13/822,794 · Granted Aug 18, 2015

Methods to produce bunyavirus replicon particles

Inventors: Jeroen Alexander Kortekaas (Zwolle, NL); Robertus Jacobus Maria Moormann (Dronten, NL)
Assignee: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
C12N7/00A61K39/12C07K14/005C12N2510/02C12N2760/12022C12N2760/12034C12N2760/12043C12N2760/12051C12N2760/12234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,109,199
App. No.
13/822,794
Granted
Aug 18, 2015
Kind
B2
Abstract

The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.

Claims (27)

1. A method for generating a recombinant, non-spreading bunyavirus replicon particle, the method comprising:

A) culturing a eukaryotic cell with growth medium;

B1) expressing T7 polymerase in the eukaryotic cell;

B2) expressing bunyavirus Gn protein and bunyavirus Gc proteins, and optionally bunyavirus NSm protein, in the eukaryotic cell, wherein said Gn and Gc proteins may form a heterodimeric polyprotein (GnGc); and wherein upon the optional expression of NSm protein, a heterotrimeric polyprotein (NSmGnGc) may form;

B3) transforming or transducing the eukaryotic cell with a vector comprising cDNA that encodes a bunyavirus L genome segment, wherein said L genome segment cDNA is flanked by a T7 promoter and cDNA of a ribozyme sequence;

B4) transforming or transducing the eukaryotic cell with a vector comprising cDNA that encodes at least part of a bunyavirus S genome segment, wherein said S genome segment cDNA comprises at least the N-gene and the 3′ and 5′ UTRs, wherein said S genome segment cDNA is flanked by a T7 promoter and cDNA of a ribozyme sequence; and, optionally,

B5) transforming or transducing the eukaryotic cell with a vector comprising cDNA that encodes a bunyavirus M genome segment from which the GnGc coding region has been functionally inactivated, wherein said M genome segment cDNA is flanked by a T7 promoter and cDNA of a ribozyme sequence;

C) following steps B1-B5, the eukaryotic cell is maintained in the growth medium and recombinant, non-spreading bunyavirus replicon particles are generated and isolated from the growth medium;

wherein the sequence of steps B1, B2, B3, B4, B5 is random and all or part of these steps may be performed simultaneously.

2. The method according to claim 1 , wherein the T7 polymerase is provided to the eukaryotic cell by transfected the eukaryotic cell with a recombinant fowlpox virus expressing said T7 polymerase.

3. The method according to claim 1 , wherein the eukaryotic cell is provided with the bunyavirus proteins of step B2) through transfection of the eukaryotic cell with a recombinant non-replicative and/or non-spreading paramyxovirus expressing said bunyavirus Gn, Gc, and/or NSm proteins.

4. The method according to claim 3 , wherein the eukaryotic cell is stably transfected or wherein the recombinant non-replicative and/or non-spreading paramyxovirus is persistently present.

5. The method according to claim 1 , wherein the eukaryotic cell is provided with the bunyavirus proteins of step B2) through transfection of the eukaryotic cell with an expression vector conditionally expressing said bunyavirus Gn, Gc, and optionally NSm proteins.

6. The method according to claim 1 , wherein the bunyavirus L genome segment and/or the S genome segment, and/or, when present, the M genome segment comprises a foreign gene.

7. The method according to claim 1 , further comprising a M, L, or S minigenome, wherein a foreign gene is present in said M, L or S-minigenome.

8. The method according to claim 1 , wherein the eukaryotic cell is a mammalian cell.

9. The method according to claim 1 , wherein the bunyavirus is Rift Valley fever virus.

10. A recombinant, non-spreading bunyavirus replicon particle produced by the method according to claim 1 .

11. The recombinant, non-spreading bunyavirus replicon particle according to claim 10 , wherein the bunyavirus L genome segment and or the S genome segment and/or, when present, the M genome segment, comprises a foreign gene.

12. The recombinant, non-spreading bunyavirus replicon particle according claim 10 , wherein the bunyavirus is Rift Valley fever virus.

13. A method for producing a bunyavirus replicon particle, the method comprising:

A) culturing a eukaryotic cell with growth medium;

B) transfecting, transforming, or transducing said eukaryotic cell with vectors expressing the bunyavirus NSm, Gn, and Gc proteins;

C) transfecting the eukaryotic cell with the recombinant, non-spreading bunyavirus replicon particle according to claim 10 .

14. A medicament or an immunogenic composition comprising the recombinant, non-spreading bunyavirus replicon particle according to claim 10 .

15. method according to claim 8 , wherein the mammalian cell is BHK-21.

16. The method according to claim 8 , wherein the mammalian cell is BSR-T7/5.

Assignments (2)
CHANGE OF NAME Recorded May 16, 2017
From: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
To: STICHTING WAGENINGEN RESEARCH
Reel/Frame 042469/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2013
From: KORTEKAAS, JEROEN ALEXANDER; MOORMANN, ROBERTUS JACOBUS MARIA
To: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
Reel/Frame 030492/0239 →
Priority Claims (1)
EP 10177709 · Sep 20, 2010 · regional
Continuity (2)
Provisional Application 61468597 · Mar 29, 2011
Related Publication 20130236493A1 · Sep 12, 2013